White-coat and masked hypertension diagnoses in chronic kidney disease patients

被引:0
|
作者
da Silva, Henrique Pereira [1 ]
Goncalves, Alessandra Bonilha [1 ]
Barretti, Pasqual [1 ]
Franco, Roberto Silva [1 ]
Banin, Vanessa Burgugi [1 ]
Silva, Vanessa dos Santos [1 ]
Martin, Luis Cuadrado [1 ]
机构
[1] Sao Paulo State Univ Unesp, Botucatu Med Sch, Dept Internal Med, Prof Mario Rubens Guimaraes Montenegro Ave, BR-18618970 Botucatu, SP, Brazil
来源
JOURNAL OF CLINICAL HYPERTENSION | 2020年 / 22卷 / 07期
关键词
ambulatory blood pressure measurement; chronic kidney disease; masked hypertension; white-coat hypertension; AMBULATORY BLOOD-PRESSURE; GUIDELINES;
D O I
10.1111/jch.13924
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The purpose of this study was to analyze which 24-hour ambulatory blood pressure measurement (ABPM) parameters should be used on masked hypertension (MH) and white-coat hypertension (WCH) diagnoses in chronic kidney disease (CKD) patients. Non-dialysis CKD patients underwent 24-hour ABPM examination between 01/27/2004 and 02/16/2012. They were followed from the 24-hour ABPM to January/2014 in an observational study. The WCH definitions tested were as follows: (a) office blood pressure (BP) >= 140/90 mm Hg and daytime ABPM BP <= 135/85 mm Hg (old criterion); and (b) office BP >= 140/90 mm Hg and 24-hour ABPM BP <= 130/80 mm Hg, daytime ABPM BP <= 135/85 mm Hg, and nighttime ABPM BP <= 120/70 mm Hg (new criterion). The MH definitions tested were as follows: (a) office BP 135/85 mm Hg (old criterion); and (b) office BP 130/80 mm Hg or daytime ABPM BP > 135/85 mm Hg or nighttime ABPM BP > 120/70 mm Hg (new criterion). The two definitions' predictive capacity was compared, regarding both WCH and MH. Cardiovascular mortality was the primary and all-cause mortality was the secondary outcome. Cox regression was adjusted to the variables: glomerular filtration rate, age, diabetes mellitus, and active smoking. There were 367 patients studied. The old criterion (exclusive mean daytime ABPM BP) was the only to distinguish sustained hypertension from WCH (adjusted HR: 3.730; 95% CI: 1.068-13.029;P = .039), regarding all-cause mortality. Additionally, the old criterion was the only one to distinguish normotension and MH, regarding cardiovascular mortality (adjusted HR: 7.641; 95% CI: 1.277-45.738;P = .026). Therefore, WCH and MH definitions based exclusively on daytime ABPM BP values (old criterion) were able to better distinguish mortality in this studied CKD cohort.
引用
收藏
页码:1202 / 1207
页数:6
相关论文
共 50 条
  • [1] White-coat and masked hypertension diagnoses in chronic kidney disease
    daSilva, Henrique Pereira
    Bonilha, Alessandra
    Barretti, Pasqua
    da Silva Franco, Roberto Jorge
    Banin, Vanessa Burgugi
    Silva, Vanessa Dos Santos
    Martin, Luis Cuadrado
    JOURNAL OF CLINICAL HYPERTENSION, 2020, 22 (04): : 709 - 710
  • [2] Masked Hypertension and White-Coat Hypertension in Chronic Kidney Disease: A Meta-analysis
    Bangash, Farhan
    Agarwal, Rajiv
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (03): : 656 - 664
  • [3] WHITE-COAT HYPERTENSION AND MASKED HYPERTENSION IN CHRONIC KIDNEY DISEASE AT THE POPULATION LEVEL IN URUGUAY
    Lujambio, I.
    Boggia, J.
    Luzardo, L.
    Robaina, S.
    Olascoaga, A.
    Krul, N.
    Da Rosa, A.
    Carusso, F.
    Noboa, O.
    JOURNAL OF HYPERTENSION, 2015, 33 : E224 - E224
  • [4] Prevalence, determinants, and clinical significance of masked hypertension and white-coat hypertension in patients with chronic kidney disease
    Tang, Hua
    Gong, Wen-Yu
    Zhang, Qun-Zi
    Zhang, Jun
    Ye, Zeng-Chun
    Peng, Hui
    Wang, Cheng
    Lou, Tanqi
    NEPHROLOGY, 2016, 21 (10) : 841 - 850
  • [5] WHITE-COAT AND MASKED HYPERTENSION IN HEMODIALYSIS PATIENTS
    Leonidou, K.
    Georgianos, P.
    Kollias, A.
    Vaios, V.
    Divanis, D.
    Roumeliotis, S.
    Varouktsi, G.
    Tsinari, A.
    Stergiou, G.
    Zebekakis, P.
    Liakopoulos, V.
    JOURNAL OF HYPERTENSION, 2024, 42
  • [6] Significance of white-coat and masked hypertension in chronic kidney disease and end-stage renal disease
    José Boggia
    Ricardo Silvariño
    Leonella Luzardo
    Oscar Noboa
    Hypertension Research, 2014, 37 : 882 - 889
  • [7] Significance of white-coat and masked hypertension in chronic kidney disease and end-stage renal disease
    Boggia, Jose
    Silvarino, Ricardo
    Luzardo, Leonella
    Noboa, Oscar
    HYPERTENSION RESEARCH, 2014, 37 (10) : 882 - 889
  • [8] WHITE-COAT HYPERTENSION AND MASKED HYPERTENSION IN HYPERTENSIVE KIDNEY TRANSPLANT RECIPIENTS
    Loutradis, Charalampos
    Korogiannou, Maria
    Xagas, Efstathios
    Marinaki, Smaragdi
    Argyris, Antonios
    Protogerou, Athanasios
    Sarafidis, Pantelis
    Boletis, John
    JOURNAL OF HYPERTENSION, 2021, 39 : E304 - E304
  • [9] Diagnosis and management of patients with white-coat and masked hypertension
    Giuseppe Mancia
    Michele Bombelli
    Gino Seravalle
    Guido Grassi
    Nature Reviews Cardiology, 2011, 8 : 686 - 693
  • [10] Masked hypertension and white-coat hypertension prognosis
    Verberk, W
    Kroon, AA
    de Leeuw, PW
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (10) : 2127 - 2127